Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies

By F. Blows, K. Driver, M. Schmidt, A. Broeks, F. V. van Leeuwen, J. Wesseling, M. Cheang, K. Gelmon, Torsten O. Nielsen, C. Blomqvist and 33 more. PLoS Medicine, 2010

1,105 citations recorded by the source corpus.

Paul Pharoah and colleagues evaluate the prognostic significance of immunohistochemical subtype classification in more than 10,000 breast cancer cases with early disease, and examine the influence of a patient's survival time on the prediction of future survival.

Subfields: Cancer Research, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/9f95f2e8dc1c38383069a58c7242b15057f86527

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. R. Siegel
2. K. Miller
3. A. Jemal
4. Børge G. Nordestgaard
5. Chad Creighton
6. Zhonghu Bai
7. Xiaofeng Dai

In Oncology

1. R. Siegel
2. A. Jemal
3. K. Miller
4. C. DeSantis
5. S. Fedewa
6. Ann Goding Sauer
7. Robert A. Smith
8. Zhonghu Bai

In Pathology and Forensic Medicine

1. A. Jemal
2. R. Siegel

Citations in the corpus

• Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. (2015, background): “Patients with TNBC often have a worse outcome than patients with other breast cancer subtypes,(3,4) with 5-year survival estimated at 70% for those with TNBC compared with 80% for all other subtypes.(5) Germline mutations in the BRCA1 breast and ovarian cancer susceptibility gene have been associate”
• Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. (2011, methodology): “02 ER(2)/PR(1) 25 110 (13) 317 (39) 275 (34) 90 (11) 27 (3) 0.”
• Breast cancer intrinsic subtype classification, clinical use and future trends. (2015, background): “Accumulating evidence has suggested that breast cancers with different histopathological and biological features exhibit distinct behaviors that lead to different treatment responses and should be given different therapeutic strategies [8].”
• The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes (2016, neutral): “01) are shown, and only associations with absolute log odds Xlog(2) were considered.”
• Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities (2016, background): “prognosis, in part because there are currently no targeted therapies for these tumors.(64,65) Some studies suggest that black women are more likely to be diagnosed with”
• UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses (2017, background): “Breast cancer involves various histopathological features known to have treatment implications [48].”
• Breast cancer statistics, 2015: Convergence of incidence rates between black and white women (2016, background): “Triple-negative breast cancers are considered to be more aggressive and have poorer prognoses, in part because there are currently no targeted therapies for these tumors.(31,32) In contrast, white women have the highest proportion of HR1/HER22 breast cancers, whereas API women have the largest propo”